Evidence map›Paper›PMID 41384044›Full record

ArticleGlomerular diseases

Evaluation of Biopsy-Based Molecular Risk Prediction in Crescentic Glomerulonephritis.

Benjamin A Adam, Kristalee Watson, Arashdeep Saini, Peter Dromparis, Ainslie Eberhart, Wirongrong Churngchow, Sridevi Koduru, Maziar Riazy, Sean J Barbour, Michael Mengel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Benjamin A AdamDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Kristalee WatsonDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Arashdeep SainiDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Peter DromparisDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Ainslie EberhartDivision of Nephrology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Wirongrong ChurngchowDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Sridevi KoduruDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Maziar RiazyDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Sean J BarbourDivision of Nephrology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Michael MengelDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Novel molecular tools have the potential to improve current clinical and histology-based risk classification systems for various medical renal diseases including glomerulonephritis (GN). We aimed to assess the utility of gene expression for improving biopsy-based risk prediction in patients with GN with and without crescent formation. Methods: This retrospective case-control study used NanoString nCounter to measure the expression of 54 previously described inflammation, nephron injury, endothelium, and crescent-related genes in 335 archival, formalin-fixed paraffin-embedded native kidney biopsies, including a 288-biopsy discovery cohort representing a broad spectrum of crescentic GN subtypes, and an independent 47-biopsy validation cohort focused on ANCA-associated crescentic GN. Clinical, histologic, and gene expression data were compared. Results: Discovery cohort analysis demonstrated increased expression of 13 genes in crescentic GN cases that developed end-stage renal disease (ESRD) versus those that did not (false discovery rate <0.05). Within the 75-biopsy subset of ANCA-associated crescentic GN cases in the discovery cohort, this 13-gene set was found to be independently predictive of ESRD in multivariate Cox proportional hazards regression analysis ( Conclusion: These results suggest that biopsy-based gene expression may provide the opportunity for improved risk stratification in crescentic GN; however, the genes evaluated in this study appear to have limited added clinical utility over existing risk scores.

Indexed as

ANCA vasculitisGene expressionGlomerulonephritisPathologyRenal biopsy

Identifiers

PMID41384044
PMCPMC12695120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.